Krasney Karen
Known title: EVP, GENERAL COUNSELCIK: 0001593086
Associated companies
Transaction History
| CAPR | ▲ Buy | Option Exercise | 24,100 | $77K | 6/25/2026 | View on chart |
| CAPR | ▼ Sell | Open Market | 24,100 | $732K | 6/25/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 400 | $1K | 6/24/2026 | View on chart |
| CAPR | ▼ Sell | Open Market | 400 | $12K | 6/24/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 500 | $2K | 6/22/2026 | View on chart |
| CAPR | ▼ Sell | Open Market | 500 | $15K | 6/22/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 25,000 | $80K | 5/1/2026 | View on chart |
| CAPR | ▼ Sell | Open Market | 25,000 | $793K | 5/1/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 693 | $963 | 3/31/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 21,488 | $80K | 3/31/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 2,819 | $9K | 3/31/2026 | View on chart |
| CAPR | ▼ Sell | Open Market | 25,000 | $753K | 3/31/2026 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 2,500 | $3K | 12/30/2025 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 8,000 | $11K | 12/13/2024 | View on chart |
| CAPR | ▲ Buy | Option Exercise | 18,932 | $26K | 11/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Capricor Therapeutics Sees Fair Value Adjustments on Deramiocel
Analysts have revised their fair value estimates for Capricor Therapeutics following new data on its lead candidate, Deramiocel. These adjustments reflect updated expectations for the drug's potential, which may influence how investors view the company's long-term outlook. The stock currently trades within a wide 52-week range, indicating significant volatility tied to these clinical developments.
Capricor Therapeutics Sees Fair Value Adjustments on Deramiocel. Analysts have revised their fair value estimates for Capricor Therapeutics following new data on its lead candidate, Deramiocel. These adjustments reflect updated expectations for the drug's potential, which may influence how investors view the company's long-term outlook. The stock currently trades within a wide 52-week range, indicating significant volatility tied to these clinical developments.